Chronic Fibrosis in Lower Urinary Tract Dysfunctions—Mechanisms and Therapeutic Options

Workshop 8

ICS Members Only
Join ICS Sign in
{{CC.VideoPaywalButtonText}} Sign in Sign in
Restricted Video
Sign in Join Now

ICS Members Only Restricted Video

Workshop Schedule


Marcus John Drake


Lori A Birder


Anthony John Kanai


Christopher Henry Fry



Aims & Objectives

90 minutes
Pure and Applied Science / Translational
Bladder Fibrosis Radiation & Ketamine Cystitis Underactive Bladder
Scientists, urologists and other healthcare workers interested in new mechanistic concepts and treatments for chronic fibrosis in lower urinary tract dysfunctions (LUTD).

This workshop will provide the latest information on the pathophysiology and clinical implications of chronic fibrosis in LUTD including radiation and ketamine cystitis, underactive bladder, bladder obstruction and congenital anomalies. The workshop will consider how changes to the quantity and subtype profiles of collagen and its deposition in the extracellular matrix (ECM) of the bladder wall will impact on changes to compliance, passive tension and active and spontaneous force generation. The therapeutic benefits and mode of action of antifibrotic agents, including the hormone, relaxin, in rescuing these pathological conditions will be presented.

Learning Objectives

  • 1) Provide up to date information on the clinical implications of chronic fibrosis in LUTD. 2) Discuss mechanisms that contribute to inflammation, collagen deposition and alterations in the ECM leading to chronic fibrosis. 3) Show findings of the therapeutic benefits of anti-fibrotic agents to increase wall compliance and enhance contractile function of bladders with increased ECM deposition. 4) Consider the cellular pathways that regulate ECM deposition.